Comparative Pharmacology
Head-to-head clinical analysis: LANTUS versus MYXREDLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LANTUS versus MYXREDLIN.
LANTUS vs MYXREDLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Long-acting recombinant human insulin analog that binds to insulin receptors, activating downstream signaling pathways to facilitate glucose uptake, inhibit gluconeogenesis, and regulate lipid and protein metabolism.
Insulin analog with rapid onset of action; lowers blood glucose by promoting peripheral glucose uptake and inhibiting hepatic glucose production, and by inhibiting lipolysis and proteolysis.
Subcutaneous injection once daily at the same time each day. Initial dose: 0.2-0.4 units/kg/day. Titrate based on blood glucose monitoring.
0.5 mg or 0.75 mg subcutaneously once daily, initially, with titration based on glycemic response; maximum dose 1.5 mg/day.
None Documented
None Documented
Terminal half-life: 24 hours (provides basal insulin coverage for 24 hours)
Terminal elimination half-life 12-15 hours in adults; prolonged to 24-30 hours in renal impairment (CrCl <30 mL/min)
Renal: minimal (degraded by insulin-degrading enzyme), biliary: negligible, fecal: negligible
Renal excretion 70% as unchanged drug; fecal/biliary elimination 30% as metabolites
Category C
Category C
Long-acting Insulin
Long-acting Insulin